688192.SS Overview

Company Profile

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.

Related stocks

000423.SZ

000423.SZ • China

46.68 CNY

4.47B USD 1Y -1.3%

000513.SZ

000513.SZ • China

30.5 CNY

4.05B USD 1Y -21.4%

600085.SS

600085.SS • China

BEIJING TONG REN TANG CO

24.28 CNY

4.98B USD 1Y -29.3%

600566.SS

600566.SS • China

HUBEI JUMPCAN PHARMACEUTICAL CO

26.7 CNY

3.68B USD 1Y +8.3%

600521.SS

600521.SS • China

ZHEJIANG HUAHAI PHARMACEUTICAL

17.45 CNY

3.91B USD 1Y -16.9%

000999.SZ

000999.SZ • China

24.82 CNY

6.18B USD 1Y -12.3%

000739.SZ

000739.SZ • China

25.4 CNY

4.4B USD 1Y +55.9%

600664.SS

600664.SS • China

HARBIN PHARMACEUTICAL GROUP CO

7.39 CNY

2.78B USD 1Y +105.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Drug Manufacturers - Specialty & Generic

Website

https://www.dizalpharma.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

52.0% p.a.

Max Drawdown (5Y)

-57.2%

Sharpe Ratio (5Y)

0.11

Beta Factor

-0.01

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Unprofitable business model: The company is currently generating net losses.

🔴 High valuation risk: Avg P/E of 90.8 (Elevated multiple compression risk)

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Elevated Short-Term Volatility: 3Y volatility (56.5%) is noticeably higher than the 5Y average (52.0%).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (52.0% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -57.2% in the extended horizon.